Shire PLC’s CEO on Why the Company is Bullish on ADHD Therapies and its $2.6 Billion Purchase of New River

Does ADHD really exist?  Very likely (although, for young boys,  it's likely one of the most over- and incorrectly diagnosed illnesses around today---and who needs drug sales reps when so many school guidance counselors, teachers and nurses are such effective promoters?)  But , I digress.  The U.K.'s Shire PLC has become a specialist in this therapeutic area....The company will acquire U.S.-based New River's Vyvanse, which has reportedly received preliminary FDA approval and is expected to receive full approval this quarter, as well as other R&D and commercial assets. Shire's Adderall's patent is due to expire in two years. Read about the new acquisition here.   Or, better yet,  tune in for Bloomberg's interview with Shire's CEO.

Play Video

Shire CEO Matthew Emmens on acquisition of New River Pharma - Bloomberg

Bloomberg - (BLOOM)

Feb. 20, 2007. 08:47 AM EST

U.K.-based pharma company will buy new River, a specialist in ADHD treatments, for $2.6 billion.